Effects of ACS in Twin With LPB: Study Protocol for a RCT

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

848

Participants

Timeline

Start Date

May 5, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

July 26, 2024

Conditions
Twin Pregnancy, Antepartum Condition or Complication
Interventions
DRUG

Betamethason Sodium Phosphate

The antecorticosteroid that will be administered to Group 1 is betamethasone, produced by Dawon Parm(Korea). It contains betamethason sodium phosphate 5.2mg(Betamethasone 4.0mg) in 1 ample(1mL). Each drug is carried in a syringe by pharmacist who does not participate in study after the patient was enrolled in the study and administered to the patient twice 24hours apart.

DRUG

Normal saline

Intramuscular injection of normal saline 3ml twice 24hours apart

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT03547791 - Effects of ACS in Twin With LPB: Study Protocol for a RCT | Biotech Hunter | Biotech Hunter